QLF31911

QLF31911 is an investigational, orally bioavailable small molecule inhibitor developed by Qilu Pharmaceutical that specifically targets the KRAS G12D mutation. KRAS G12D is a prominent oncogenic driver found in a significant proportion of pancreatic, colorectal, and non-small cell lung cancers. By selectively binding to the G12D mutant form of the KRas protein, QLF31911 prevents the protein from activating downstream signaling pathways, such as the MAPK/ERK and PI3K/AKT pathways, which are essential for tumor cell growth and survival. Unlike KRAS G12C inhibitors that utilize covalent bonding, KRAS G12D inhibitors typically function through high-affinity non-covalent binding to lock the protein in its inactive GDP-bound state. The drug is currently being evaluated in Phase 1 clinical trials for patients with advanced malignant tumors harboring the KRAS G12D mutation.